Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?

Endocrinology

Volumn 147, Issue 9, 2006, Pages 4056-4066

  Lupu, Ruth ^a,b   Menendez, Javier A ^c,d  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C 75; CERULENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTRADIOL RECEPTOR; ESTROGEN RECEPTOR; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER GENETICS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DRUG INHIBITION; ENDOMETRIUM CANCER; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HORMONE METABOLISM; HUMAN; LIPOGENESIS; PRIORITY JOURNAL; RNA INTERFERENCE; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; ESTRADIOL; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; RECEPTORS, ESTRADIOL; RNA, SMALL INTERFERING; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION;

EID: 33747807398     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0486     Document Type: Short Survey

References (102)

1. Jensen EV, Jordan VC 2003 The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9:1980-1989
2. Jordan VC 2003 Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205-213
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
4. Dunn BK, Wickerham DL, Ford LG 2005 Prevention of hormone-related cancers: breast cancer. J Clin Oncol 23:357-367
5. Osborne CK, Zhao H, Fuqua SA 2000 Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18:3172-3186
6. Gradishar WJ, Jordan VC 2003 Advances in endocrine therapy for the treatment and prevention of breast cancer. Cancer Chemother Biol Response Modif 21:211-222
7. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, et al 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117-120
8. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM 1994 Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537
9. Osipo C, Liu H, Meeke K, Jordan VC 2004 The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. Exp Biol Med (Maywood) 229:722-731
10. Kurokawa H, Arteaga CL 2003 ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 9(1 Pt 2):511S-515S
11. Kurokawa H, Arteaga CL 2001 Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 7(12 Suppl):4436s-4442s
12. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935
13. Osborne CK, Shou J, Massarweh S, Schiff R 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11(2 Pt 2):865s-870s
14. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC 2000 Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6:2028-2036
15. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC 2003 Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95:1597-1608
16. Smith IE, Dowsett M 2003 Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442
17. Simpson ER, Dowsett M 2002 Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 57:317-338
18. Santen RJ, Harvey HA 1999 Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 6:75-92
19. Goss PE, Strasser K 2001 Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894
20. Goss PE, Strasser K 2002 Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs 62:957-966
21. Lewis JS, Cheng D, Jordan VC 2004 Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 90:944-949
22. Wakil S 1989 Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28:4523-4530
23. Weiss L, Hoffmann GE, Schreiber R, Andres H, Fuchs E, Korber E, Kolb HJ 1986 Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe Seyler 367:905-912
24. Clarke SD 1993 Regulation of fatty acid synthase gene expression: an approach for reducing fat accumulation. J Anim Sci 71:1957-1965
25. Katsurada A, Iritani N, Fukuda H, Matsumara Y, Nishimoto N, Noguchi T, Tanaka T 1990 Effects of nutrients and hormones on transcriptional and post-transcriptional regulation of fatty acid synthase in rat liver. Eur J Biochem 190:427-433
26. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR 1994 Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379-6383
27. Kuhajda FP 2000 Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16:202-208
28. Menendez JA, Lupu R 2004 Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz) 52:414-426
29. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R 2004 Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal α-linolenic and γ-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol 24:1369-1383
30. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP 1997 Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3:2115-2120
31. Alo PL, Visca P, Botti C, Galati GM, Sebastiani V, Andreano T, Di Tondo U, Pizer ES 2001 Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol 116:129-134
32. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K 2003 Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 1:362-375
33. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W, Verhoeven G 2000 Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 88:176-179
34. Bull JH, Ellison G, Patel A, Muir G, Walker M, Underwood M, Khan F, Paskins L 2001 Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 84:1512-1519
35. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U 1996 Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474-482
36. Alo PL, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S, Botti C, Serpieri DE, Di Tondo U 1999 Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85:35-40
37. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Soerensen FB 1995 The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol 176:343-352
38. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP 1996 Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56:2745-2747
39. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP 1996 Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189-1193
40. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP 2000 Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60:213-218
41. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV 2003 RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63:3799-3804
42. Kusakabe T, Maeda M, Hoshi N, Sugino T, Watanabe K, Fukuda T, Suzuki T 2000 Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem 48:613-622
43. Escot C, Joyeux C, Mathieu M, Maudelonde T, Pages A, Rochefort H, Chalbos D 1990 Regulation of fatty acid synthetase ribonucleic acid in the human endometrium during the menstrual cycle. J Clin Endocrinol Metab 70:1319-1324
44. Pizer ES, Kurman RJ, Pasternack GR, Kuhajda FP 1997 Expression of fatty acid synthase is closely linked to proliferation and stromal decidualization in cycling endometrium. Int J Gynecol Pathol 16:45-51
45. Chalbos D, Joyeux C, Galtier F, Escot C, Chambon M, Maudelonde T, Rochefort H 1990 Regulation of fatty acid synthetase by progesterone in normal and tumoral human mammary glands. Rev Esp Fisiol 46:43-46
46. Chalbos D, Chambon M, Ailhaud G, Rochefort H 1987 Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262:9923-9926
47. Pizer ES, Lax SF, Kuhajda FP, Pasternack GR, Kurman RJ 1998 Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer 83:528-537
48. Swinnen JV, Ulrix W, Heyns W, Verhoeven G 1997 Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci USA 94:12975-12980
49. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen JV 2001 Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 15:1817-1828
50. Lacasa D, Le Liepvre X, Ferre P, Dugail I 2001 Progesterone stimulates adipocyte determination and differentiation 1/sterol regulatory elementbinding protein 1c gene expression: potential mechanism for the lipogenic effect of progesterone in adipose tissue. J Biol Chem 276:11512-11516
51. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G 1997 Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57:1086-1090
52. Joyeux C, Rochefort H, Chalbos D 1989 Progestin increases gene transcription and messenger ribonucleic acid stability of fatty acid synthetase in breast cancer cells. Mol Endocrinol 3:681-686
53. Menendez JA, Oza BP, Colomer R, Lupu R 2005 The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol 26:1507-1515
54. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV 2002 Role of the phosphatidylinositol 3́-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62:642-646
55. Menendez JA, Colomer R, Lupu R 2005 Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med Hypotheses 64:342-349
56. Kotzka J, Muller-Wieland D, Koponen A, Njamen D, Kremer L, Roth G, Munck M, Knebel B, Krone W 1998 ADD1/SREBP-1c mediates insulin-induced gene expression linked to the MAP kinase pathway. Biochem Biophys Res Commun 249:375-379
57. Fleischmann M, Iynedjian PB 2000 Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem J 349:13-17
58. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M 2003 Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707-715
59. Yang YA, Morin PJ, Han WF, Chen, T, Bornman DM, Gabrielson EW, Pizer ES 2003 Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132-137
60. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC 2004 Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64:2212-2221
61. Li JN, Mahmoud MA, Han WF, Ripple M, Pizer ES 2000 Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res 261:159-165
62. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES 2002 Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80-90
63. Yang YA, Morin PJ, Han WF, Chen T, Bornman DM, Gabrielson EW, Pizer ES 2003 Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132-137
64. Bertile F, Raclot T 2004 mRNA levels of SREBP-1c do not coincide with the changes in adipose lipogenic gene expression. Biochem Biophys Res Commun 325:827-834
65. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R 2004 Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101:10715-10720
66. Menendez JA, Vellon L, Colomer R, Lupu R 2005 Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 18:375-385
67. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM 2003 Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63:132-139
68. Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R 2004 Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog 41:164-178
69. Menendez JA, Decker JP, Lupu R 2005 In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J Cell Biochem 94:1-4
70. Menendez JA, Oza BP, Atlas E, Mehmi I, Lupu R, Fatty acid synthase (FAS) inhibitor C75 induces hyperactivation of ERK1/2 MAPK-estrogen receptor α (ER-α) cross-talk, loss of ER-α expression, inhibition of cell growth, and apoptotic cell death in hormone-dependent breast cancer cells. Proc 15th Annual AACR-NCI-EORTC Symposium, San Francisco, CA, 2003 (Abstract A157)
71. Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R 2004 Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene 23:4945-4958
72. Menendez JA, Oza BP, Atlas E, Vazquez-Martin A, Colomer R, Lupu R, The anorectic fatty acid synthase (FAS) inhibitor C75 regulates genomic and nongenomic estrogen receptor-α activities in breast cancer cells. Proc 95th Annual AACR, Orlando, FL, 2004, Late-Breaking Abstract LB268
73. Menendez JA, Rubinstein W, Lupu R, Inhibition of fatty acid synthase (FAS) activity reverses tamoxifen resistance in Her-2/neu-overexpressing breast cancer cells. Proc 96th Annual AACR, Anaheim, CA, 2005 (Abstract 5072)
74. Menendez JA, Lupu R, Heregulin induces transcriptional activation of breast cancer-associated fatty acid synthase (FAS) gene expression by an autocrine mechanism that requires activation of Her-2/neu, MAPK and PI-3′K. Proc 96th Annual AARC, Anaheim, CA, 2005 (Abstract 3670)
75. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F 2001 PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20:6050-6059
76. Migliaccio A, Castoria G, Di Domenico M, De Falco A, Bilancio A, Auricchio F 2002 Src is an initial target of sex steroid hormone action. Ann NY Acad Sci 963:185-190
77. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292-1300
78. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol Endocrinol 15:1344-1359
79. Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, Stoica A 2003 Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22:7998-8011
80. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES 2005 Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4:1686-1696
81. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272:10882-10894
82. Planas-Silva MD, Weinberg RA 1997 Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059-4069
83. Foster JS, Wimalasena J 1996 Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 10:488-498
84. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM 2000 Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 97:9042-9046
85. Thupari JN, Pinn ML, Kuhajda FP 2001 Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285:217-223
86. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV, Kuhajda FP 2003 Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 63:7330-7337
87. Lelliott CJ, Lopez M, Curtis RK, Parker N, Laudes M, Yeo G, Jimenez-Linan M, Grosse J, Saha AK, Wiggins D, Hauton D, Brand MD, O'Rahilly S, Griffin JL, Gibbons GF, Vidal-Puig A 2005 Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J 19:1108-1119
88. Nakamura I, Kimijima I, Zhang GJ, Onogi H, Endo Y, Suzuki S, Tuchiya A, Takenoshita S, Kusakabe T, Suzuki T 1999 Fatty acid synthase expression in Japanese breast carcinoma patients. Int J Mol Med 4:381-387
89. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES 2005 Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4:1686-1696
90. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F; NCI-Naple Breast Cancer Group 2005 Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721-747
91. Sinilnikova OM, Ginolhac SM, Magnard C, Leone M, Anczukow O, Hughes D, Moreau K, Thompson D, Coutanson C, Hall J, Romestaing P, Gerard JP, Bonadona V, Lasset C, Goldgar DE, Joulin V, Venezia ND, Lenoir GM 2004 Acetyl-CoA carboxylase α gene and breast cancer susceptibility. Carcinogenesis 25:2417-2424
92. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV 2005 RNA interference-mediated silencing of the acetyl-CoA-carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65:6719-6725
93. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V 2006 Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res 66:5287-5294
94. Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, Lenoir GM, Venezia ND 2002 BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 21:6729-6739
95. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, Foufelle F, Billaud M, Lenoir GM, Venezia ND 2006 BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281:3172-3181
96. Ray H, Moreau K, Dizin E, Callebaut I, Venezia ND 2006 ACCA phosphopeptide recognition by the BRCT repeats of BRCA1. J Mol Biol 359:973-982
97. Brown SB, Maloney M, Kinlaw WB 1997 "Spot 14" protein functions at the pretranslational level in the regulation of hepatic metabolism by thyroid hormone and glucose. J Biol Chem 272:2163-2166
98. Moncur JT, Park JP, Memoli VA, Mohandas TK, Kinlaw WB 1998 The "Spot 14" gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers: implications for control of tumor metabolism. Proc Natl Acad Sci USA 95:6989-6994
99. Cunningham BA, Moncur JT, Huntington JT, Kinlaw WB 1998 "Spot 14" protein: a metabolic integrator in normal and neoplastic cells. Thyroid 8:815-825
100. Wells WA, Schwartz GN, Morganelli PM, Cole BF, Gibson JJ, Kinlaw WB 22 March 2006 Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat [Epub ahead of print]
101. Martel PM, Bingham CM, McGraw CJ, Baker CL, Morganelli PM, Meng ML, Armstrong JM, Moncur JT, Kinlaw WB 2006 S14 protein in breast cancer cells: direct evidence of regulation by SREBP-1c, superinduction with progestin, and effects on cell growth. Exp Cell Res 312:278-288
102. Menendez JA, Lupu R 2006 Response: effect of α-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene. J Natl Cancer Inst 98:718-720